Citius Pharmaceuticals Interest Expense 2011-2025 | CTXR

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Citius Pharmaceuticals

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	10.8 K	15.7 K	16.4 K	15.8 K	851 K	8.99 K	7.5 K	93.1 K	105 K	33.3 K	704

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
851 K	704	105 K

Quarterly Interest Expense Citius Pharmaceuticals

2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10.8 K	2.93 K	3.94 K	3.97 K	12.2 K	4.24 K	3.98 K	3.99 K	12.2 K	4.14 K	3.99 K	4 K	12 K	3.9 K	4 K	3.38 K	66.8 K	33.7 K	3.38 K	13.2 K	-	4.44 K	13.2 K	87 K	7.5 K	7.5 K	87 K	7.5 K	109 K	33.6 K	7.5 K	35.2 K	-	-	893	784	-	655	3.88 K	372	387	220	372

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
109 K	220	15.8 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Amphastar Pharmaceuticals AMPH	4.08 M	$ 25.27	-2.43 %	$ 1.22 B	USA
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
Arbutus Biopharma Corporation ABUS	459 K	$ 4.75	1.61 %	$ 788 M	Canada
Aclaris Therapeutics ACRS	2.95 M	$ 3.26	-3.12 %	$ 252 M	USA
AlloVir ALVR	1.19 M	-	4.14 %	$ 49.1 M	USA
Adaptimmune Therapeutics plc ADAP	-807 K	-	-15.15 %	$ 60.3 M	Britain
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
Aeglea BioTherapeutics AGLE	-20.7 M	-	-	$ 1.01 B	USA
Ascendis Pharma A/S ASND	65.5 M	$ 220.27	4.81 %	$ 5 B	Danmark
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Enlivex Therapeutics Ltd. ENLV	874 K	$ 0.91	-5.01 %	$ 18.7 M	Israel
Can-Fite BioPharma Ltd. CANF	227 K	$ 0.28	-2.28 %	$ 609 M	Israel
Alterity Therapeutics Limited ATHE	2.28 K	$ 3.3	-3.51 %	$ 7.94 B	Australia
Brickell Biotech BBI	5 K	-	-5.38 %	$ 6.06 M	USA
BeiGene, Ltd. BGNE	-12.6 M	-	0.49 %	$ 251 B	Cayman-islands
Bellicum Pharmaceuticals BLCM	2.66 M	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	910 K	-	-7.31 %	$ 87 M	USA
Benitec Biopharma BNTC	-126 K	$ 12.05	-7.06 %	$ 496 M	USA
Aytu BioScience AYTU	-512 K	$ 2.34	2.59 %	$ 14.7 M	USA
Arena Pharmaceuticals ARNA	4.16 M	-	-6.81 %	$ 3.04 B	USA
Baudax Bio BXRX	1.36 M	-	0.59 %	$ 63 K	USA
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
Catalyst Biosciences CBIO	1.04 M	$ 14.01	-8.49 %	$ 922 M	USA
ChromaDex Corporation CDXC	3 K	-	-0.88 %	$ 598 M	USA
Axon Enterprise AXON	286 M	$ 566.18	-2.56 %	$ 42.9 B	USA
Cerus Corporation CERS	1.98 M	$ 2.16	0.47 %	$ 399 M	USA
Checkpoint Therapeutics CKPT	344 K	-	-	$ 169 M	USA
Caladrius Biosciences CLBS	-257 K	-	-16.75 %	$ 25.8 M	USA
Clovis Oncology CLVS	444 K	-	-7.23 %	$ 13 M	USA
Biogen BIIB	250 M	$ 174.42	1.11 %	$ 25.4 B	USA
BioVie BIVI	4.3 M	$ 1.42	-5.96 %	$ 2.1 M	USA
Celldex Therapeutics CLDX	927 K	$ 27.36	-2.09 %	$ 1.76 M	USA
Cortexyme CRTX	-102 K	-	-1.05 %	$ 67.1 M	USA
Deciphera Pharmaceuticals DCPH	16.4 M	-	-	$ 2.18 B	USA
Biohaven Pharmaceutical Holding Company Ltd. BHVN	-7.26 M	$ 11.54	0.87 %	$ 746 M	USA